Related Experiment Video

Updated: Jul 4, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Multi-functional nanocarriers to overcome tumor drug resistance

Lara S Jabr-Milane1, Lilian E van Vlerken, Sunita Yadav

  • 1Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 110 Mugar Life Sciences Building, Boston, MA 02115, USA.

Cancer Treatment Reviews
|June 10, 2008
PubMed

Insights

Nanotechnology offers solutions to combat multi-drug resistance (MDR) in cancer. Engineered nanocarriers enhance drug delivery and overcome resistance in solid tumors, showing promise in preclinical studies.

Area of Science:

  • Oncology
  • Nanomedicine
  • Drug Delivery

Background:

  • Multi-drug resistance (MDR) is a significant challenge in cancer chemotherapy.
  • Tumor cells develop MDR phenotypes influenced by microenvironmental factors.

Purpose of the Study:

  • To review nanotechnology-based delivery systems for overcoming MDR in solid tumors.
  • To highlight engineered nanocarriers for enhanced tumor targeting and drug delivery.

Main Methods:

  • Development of engineered nanocarriers utilizing passive and active targeting strategies.
  • Design of multi-functional nanocarriers for simultaneous or sequential therapeutic agent delivery.
  • Combination of nanocarrier delivery with energy-based modalities (sound, heat, light).

Main Results:

  • Engineered nanocarriers demonstrate enhanced tumor-targeted delivery.
  • Multi-functional nanocarriers effectively overcome MDR by modulating cellular processes and enhancing drug efficacy.
  • Preclinical studies show significant promise for nanocarriers in treating refractory MDR tumors.

Conclusions:

  • Nanotechnology-based delivery systems are a promising strategy to overcome MDR in cancer.
  • Multi-functional nanocarriers offer a versatile platform for enhancing cancer therapy effectiveness.
  • Further research and preclinical validation support the clinical translation of these nanocarriers.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.